M&A / Deals Eli Lilly maintains M&A streak with $202m Engage Bio buyout Pharmaceutical TechnologyEli Lilly's takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026. Read full story Post navigation Previous: FUJIFILM opens new iPSC facility in Madison, USNext: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026